Table of contents
In This Issue
p85 | doi:10.1038/nrd1023
Editorial: Facing our demons
p87 | doi:10.1038/nrd1026
Research Highlights
Steroids: Building biosynthetic routes in yeast
p89 | doi:10.1038/nrd1019
Inflammatory diseases: Setting a trap for cytokines
p90 | doi:10.1038/nrd1006
Antifertility drugs: Fast-track to a male pill?
p90 | doi:10.1038/nrd1017
Antihypertensive treatments: ALLHATs off to the golden oldie
p91 | doi:10.1038/nrd1022
Diabetes: How DPP-IV takes a bite
p92 | doi:10.1038/nrd1016
Endocannabinoid system: FAAH better anxiolytics?
p92 | doi:10.1038/nrd1024
Arthritis: Oxygen burst may be crucial
p93 | doi:10.1038/nrd1018
In brief
Lead Discovery | Genomics | Hormone Receptors | Gene Therapy
p93 | doi:10.1038/nrd1025
Patent watch
Markman rules | No patent for Harvard oncomouse in Canada
p94 | doi:10.1038/nrd1020
Ion channels: Fluid control
p94 | doi:10.1038/nrd1021
News and Analysis
From the analyst's couch
New drug approvals for 2002
p95 | doi:10.1038/nrd1014
Fresh from the Pipeline
Ezetimibe
p97 | doi:10.1038/nrd1015
Reviews
Kinases as therapeutic targets for heart failure
Chris J. Vlahos, Susan A. McDowell & Angela Clerk
p99 | doi:10.1038/nrd1009
Understanding biofilm resistance to antibacterial agents
David Davies
p114 | doi:10.1038/nrd1008
Molecular imaging in drug discovery and development
Markus Rudin & Ralph Weissleder
p123 | doi:10.1038/nrd1007
Article series: Case Histories
A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole
Lars Olbe, Enar Carlsson & Per Lindberg
p132 | doi:10.1038/nrd1010
The basics of mass spectrometry in the twenty-first century
Gary L. Glish & Richard W. Vachet
p140 | doi:10.1038/nrd1011
Perspectives
Article series: A guide to drug discovery
Opinion
Modern biomedical research: an internally self-consistent universe with little contact with medical reality?
David F. Horrobin
p151 | doi:10.1038/nrd1012
Opinion
Protein Folding and Disease: a view from the first Horizon Symposium
Christopher M. Dobson
p154 | doi:10.1038/nrd1013
